The calcium-activated chloride channel gene family is clustered in the 1p31 region, which is frequently deleted in sporadic breast cancer. Recent studies have indicated the association of the second member of this gene family (CLCA2) with the development of breast cancer and metastasis. We have now shown the absence of expression of CLCA2 in several breast cancer tumours and cell lines, which confirms the results from other reports. When overexpressed in CLCA2-negative cell lines, their tumorigenicity and metastasis capability were significantly reduced, suggesting a tumour suppressor role for CLCA2 in breast cancer. The mechanisms behind the silencing of CLCA2 in breast cancer, however, have not been elucidated to date. Although we were able to identify CLCA2 mutations in breast cancers, somatic mutations are not the major cause of CLCA2 gene silencing. On the other hand, treatment of breast cancer CLCA2-negative cell lines with demethylating agents was able to restore CLCA2 expression, suggesting an epigenetic inactivation of this gene. Bisulphite-sequencing of the promoterassociated CpG island of the CLCA2 gene in breast tumours demonstrated that the absence of expression in these tumours was caused by hypermethylation of the promoter CpG island. In contrast, in breast cancer cell lines, tumours, and control cell lines that express CLCA2, a much lower level, and often absence, of methylation of the promoter were demonstrated. These findings demonstrate that CLCA2 is frequently inactivated in breast cancer by promoter region hypermethylation, which makes it an excellent candidate for the 1p31 breast cancer tumour suppressor gene.
Introduction
Overall, breast cancer accounts for 32% of all new cases of cancer in women. The majority of hereditary cases of breast cancers can be accounted for by germline mutations in BRCA1 and BRCA2 genes (Antoniou et al., 2003) . Only 5-10% of cases, however, have a family history of tumours and, in the 90% of breast cancer cases which occur sporadically, both the BRCA1 and BRCA2 genes have been shown not to be involved. To date, several other genes, with tumour suppression activity, have been identified to be involved in the development and progression of breast cancer.
Positional cloning has been the most successful strategy for isolating tumour suppressor genes to date (Collins, 1992) . This approach, however, requires that the chromosomal location of the gene is known. Possibly, the most powerful indicator of the location of these genes in sporadic tumours has come from loss of heterozygosity (LOH) studies (Cavenee et al., 1983) . Once a small region of frequent LOH has been identified, it is then possible to use positional cloning strategies to isolate candidate genes from the region. Although there is evidence that genes in chromosome regions 11p15 (Lichy et al., 1998; Roy et al., 2003) and 17p13 (Hoff et al., 2001 ) may be important in breast cancer tumorigenesis, chromosome 1 is the most frequently involved in rearrangements in sporadic tumours (Hoggard et al., 1995; Nagai et al., 1995; Tsukamoto et al., 1998) . These aberrations frequently result in loss of material from the short arm of chromosome 1 (1p). Molecular studies have indicated that at least 50% of tumours show LOH for genetic markers on 1p (Antoniou et al., 2003) , and recently it has been shown, using microsatellite markers, that LOH of the 1p31 region occurs in 60% of breast tumours (Hoggard et al., 1995) . The common region of overlap is reportedly between the D1S207 and D1S2876 loci, with an estimated genomic size of 3.5 Mbp, and contains several known and predicted genes (White et al., 1998; Su et al., 1999; Sossey-Alaoui et al., 2001) .
In higher eukaryotes, DNA is methylated only at cytosines located 5 0 to guanosine in the CpG dinucleotide (Holliday and Grigg, 1993) . This modification has important regulatory effects on gene expression, especially when CpG-rich regions, located in the promoter regions of many genes are involved (Bird, 2002) . Aberrant methylation of the normally unmethylated CpG islands has been documented as a relatively frequent event in immortalized and transformed cells (Antequera et al., 1993) , and has been associated with transcriptional inactivation of defined tumour suppres-sor genes in human cancers (Esteller, 2002) . In this case, instead of coding region mutations, promoter region hypermethylation provides an alternative means of eliminating tumour suppressor gene function. Analysing the methylation status of CpG islands of genes from the 1p31 region, therefore, is an important strategy to identify breast cancer tumour suppressor genes. The analysis of CpG islands in gene promoter regions can now be achieved by sequencing bisulphite-modified DNA, a technique that enables the methylation status of every cytosine residue within a sequence to be determined (Frommer et al., 1992; Clark et al., 1994; Grigg and Clark, 1994) .
During our screening for breast cancer candidate genes from chromosome region 1p31, we identified the CLCA2 gene as being downregulated in several primary breast tumours and cell lines, confirming the findings reported by . In the present report, we show that it is the hypermethylation of the CLCA2 promoter that is the major cause of CLCA2 silencing in breast cancer. We demonstrate that the promoter region is frequently methylated in breast tumours and cell lines using bisulphite DNA sequencing. We also demonstrate that missense mutations in the coding sequence of CLCA2 can also be detected, although to a much lesser extent, in breast tumours. Our results support the role of CLCA2 as a tumour suppressor gene from the 1p31 region that is apparently deleted in more than 50% of sporadic breast tumours.
Results

CLCA2 is downregulated in breast cancer
To investigate the expression distribution of the CLCA2 gene, we performed RT-PCR analysis of RNA from various human adult and fetal tissues. CLCA2 is primarily expressed in the breast and lung (Figure 1a ). This result confirms the previously reported data (Agnel et al., 1999; . CLCA2 expression is also detected in the placenta (Figure 1a) . We also analysed nine breast cancer cell lines, including the immortalized MCF10A cell line, that is derived from normal breast epithelium, and is widely accepted as nontumorigenic breast control (Soule et al., 1990) . A total of 12 primary breast tumours and their matching normal tissues were also analysed for expression of CLCA2 using RT-PCR. Only four out of nine cell lines, including MCF10A (Figure 1b) , and three primary tumours out of the 12 analysed ( Figure 1c) showed CLCA2 RNA expression. Similar results were reported by . None of the primary tumours or cell lines that showed RNA expression had mutations in the coding sequence of the CLCA2 gene (see below).
CLCA2 gene is not commonly mutated in breast cancer
We analysed the 14 coding exons from a total of 58 breast tumours and nine cell lines using WAVEt DHPLC as described previously (Sossey-Alaoui et al., 2002b) . We detected three different missense substitutions in four primary breast tumours (Table 1) . None of these substitutions were found in the matching normal DNA or in 200 control chromosomes. The Q306E missense mutation was detected in two breast tumours, including tumour 9711, and the D326N missense mutation was detected in tumour 9699 (Table 1, Figure 2b ). Both these mutations are located either close to (Q306E) or within (D326N) an evolutionarily conserved functional domain, that is, the von Willebrand factor (vWF) type A domain (VWA) (Figure 2c ). Furthermore, both the 9711 and 9699 tumours, where missense mutations were found (Table 1) , did not show any RNA expression of CLCA2 (Figure 1c) . The Q812R missense mutation seen in tumour 534 (Table 1, Figure 2b ) does not map to any known functional domain in the CLCA2 protein, but changes an evolutionarily conserved glutamine to arginine (Figure 2c ). The G to A substitution, located 10 nucleotides before the accepting splice site of exon 4, was detected in three primary breast tumours, but not in their matching normal DNAs or in 200 normal chromosomes (Table 1) .
Tumour 590 has a second nucleotide substitution (T to G) only four nucleotides upstream of the acceptor splice site of exon 5. Two conserved changes, which did not affect the amino acid at the location of the nucleotide change (A334A and R586R), were detected in three other primary breast tumours (Table 1) . These changes were also detected in normal DNAs and, therefore, were considered polymorphisms rather than disease causing mutations. Finally, a polymorphic intronic nucleotide substitution was found in four tumours as well as in several normal samples (Table 1) .
Promoter hypermethylation is the major cause of the CLCA2 gene silencing in breast cancer tumours and cell lines
Neither the MDA-MB-231 nor MDA-MB-435 breast cancer cell lines showed expression of CLCA2 when analysed by RT-PCR ( Figure 1b) . However, treatment of these two cell lines with the demethylating agent 5-aza-2 0 -dC was able to restore CLCA2 expression to at least 50% of the expression level of b-actin (Figure 3a) . Cell-line treatment with 5-aza-2 0 -dC was also able to restore the expression of CLCA2 in MCF7, SKBr3 and T47D cell lines (Figure 3b ), although to levels much lower compared to the ones observed in MDA-MB-231 and MDA-MB-435. A noticeable increase in the expression levels of CLCA2 was also detected in the MDA-MB-468 and BT549 cell lines (Figure 3b ). This observation prompted us to analyse the methylation status of the CLCA2 promoter region in these cell lines. The CLCA2 promoter region was determined by the presence of a CpG island upstream of the first coding exon of CLCA2, using the PromoterInspector software (Figure 4a, b) . After bisulphite modification of cell-linegenomic DNA, and PCR amplification of the CLCA2 promoter region, at least 10 alleles for each cell line were sequenced ( Figure 5a ). Figure 2 WAVEt-DHPLC mutation analysis of CLCA2 in breast tumour 534 (a) and tumour 9699 (b). In the absence of mutations, the two alleles of CLCA2 form a homoduplex (HM), which elutes from the column at the same point. Any mismatch due to mutations leads to the formation of a heteroduplex (HT), which elutes earlier. Only homoduplexes are detected in the normal DNAs, but the corresponding tumour DNAs show heteroduplexes. When the DNAs showing the heteroduplexes were sequenced, the presence of a heterozygous base change was seen (double peak at *). Tumour 534 has an A 2435 G substitution in exon 14 (Gln812Arg), and tumour 9699 has a G 976 A substitution in exon 7 (Asp326Asn). The sequence of the opposite strand of exon 7 is shown. The restriction enzymes that were used to verify the authenticity of the mutations are given in parenthesis. We also sequenced bisulphite-treated DNA from the 12 primary breast tumours, described above, and found that they also exhibited tumour-specific hypermethylation ( Figure 5b ). The CLCA2 promoter hypermethylation clearly correlated with the presence of expression of CLCA2 in cell lines and tumours. Furthermore, all cell lines with promoter methylation showed reduced or absent CLCA2 RNA expression, whereas cell lines and primary tumours with apparently normal CLCA2 expression levels did not exhibit hypermethylation of the promoter. At the same time, methylation of the CLCA2 promoter region was considerably reduced in cell lines treated with the demethylating agent 5-aza-2 0 -dC (Figure 5a ), while the expression of CLCA2 RNA was restored. CLCA2-promoter methylation was not detected in two samples, derived from normal breast tissue, as well as in MCF10A cell line.
Discussion
Aberrant methylation of normally unmethylated promoter-associated CpG islands has commonly been studied as the epigenetic mechanism associated with the transcriptional silencing of known and putative tumour suppressor genes (Baylin and Herman, 2000; Garinis et al., 2002) . Selected examples include the BRCA1, ER, PR, p16, SLIT2, FHIT and LOT1 genes, which have now been identified to be epigenetically silenced in breast cancer (Catteau et al., 1999; Zochbauer-Muller et al., 2001; Dallol et al., 2002; Esteller, 2002; Abdollahi et al., 2003) . Hypermethylation of gene promoter regions is now widely accepted as being responsible for tumour suppressor gene silencing in a variety of human cancers (Garinis et al., 2002) .
The CLCA2 gene family is a novel family of calciumactivated chloride channels (Pauli et al., 2002) . Several members of this family have been cloned from different mammalian species with distinct, highly specific expression patterns (Gruber et al., 1998 . All four members of the human CLCA gene family cluster on the Figure 5 Methylation analysis of the CpG island of the CLCA2 gene in breast cancer. Genomic DNA was isolated from the indicated tumours or cell lines and analysed for methylation by direct bisulphite sequencing. Bisulphite-PCR products from breast cancer cell lines (a), and from normal breast and breast tumours (b) were subcloned into the pCR21 vector and sequenced. The ratio of all methylated sites from 10 clones was determined and recorded as a percentage. The methylation status of CpG residues 1-21 is indicated by shading, black (methylated), white (unmethylated) and grey (partially methylated)
Epigenetic silencing of CLCA2 in breast cancer X Li et al short arm of chromosome 1 at 1p31, a region that is frequently deleted in breast cancer (Hoggard et al., 1995; Nagai et al., 1995; Tsukamoto et al., 1998; Su et al., 1999; Sossey-Alaoui et al., 2001) . However, only CLCA2 gene expression was shown to be downregulated in breast cancer , this study). Loss of CLCA2 expression in human breast cancer appears to be closely associated with tumorigenicity, because neither breast tumours nor tumorigenic breast cancer cell lines were found to express CLCA2 (Figure 1 ). On the other hand, normal breast epithelial cells and the spontaneously immortalized, non-tumorigenic normal epithelial breast cells (MCF10A) all express CLCA2 (Figure 1) . Furthermore, when CLCA2 expression was re-established in breast cancer cell lines, their tumorigenicity was attenuated (at least for MDA-MB-231 and MBA-MD-435 cell lines), as judged by the results of anchorage-independent growth, migration, and in vitro invasion suppression assays (Elble and Pauli, 2001 ). All these experiments strongly suggest that CLCA2 is involved in the development of breast cancer. The mechanism behind the suppression of CLCA2 activity, however, has not been elucidated to date. The purpose of this study was to determine the molecular mechanisms that are responsible for the silencing of the CLCA2 gene in breast cancer. We have shown the presence of missense mutations in the coding region of the CLCA2 gene in a small group of tumours (Table 1, Figure 2 ). These mutations are located in evolutionarily conserved functional domains and so are likely to affect the function of CLCA2. We have also identified two nucleotide substitutions that are located within 10 nucleotides or less of the exon splice junctions. These mutations could possibly alter the splicing of the CLCA2 transcript and, therefore, suppress its function by generating an aberrant, unstable splice form of the CLCA2 transcript. Unfortunately, in the absence of tissue material from the tumours where these mutations were found, it remains difficult to verify this hypothesis. Most of the nucleotide mutations that we found in breast tumours were detected in heterozygous form. This could be explained by the presence of contaminating normal tissue with the tumour during the time the samples were collected. Overall, nucleotide substitutions in the CLCA2 gene are not the major reason for alteration of CLCA2 function in breast tumours, since they are not frequent events.
We have shown that treatment of breast cancer cell lines, which do not express CLCA2 (see Figure 1b) , with the demethylating agent 5-aza-2 0 -dC was able to restore the expression of CLCA2, even though to different degrees, in all five cell lines (Figure 3a, b) . 5-Aza-2 0 -dC treatment was also able to noticeably increase the expression levels of CLCA2 in cell lines that normally express this gene, namely MDA-MB-468 and BT549 (Figure 3b ). This observation strongly supports the idea that the silencing of the CLCA2 gene is due to DNA methylation. We have identified a CpG island in the upstream sequence of exon 1 and into the promoter of the CLCA2 gene, as determined by sequence analysis using the PromotorInspector software, which suggest that methylation in CpG dinucleotides may play a role in silencing gene expression. We confirmed this hypothesis by sequencing bisulphite-treated DNA from breast cancer cell lines and breast tumours (Figure 5a, b) . The degree of CLCA2-CpG methylation in breast tumours and cell lines clearly correlates with the levels of expression of CLCA2 in these samples. All the breast tumours and cell lines, where no, or very low expression of CLCA2, was detected, showed hypermethylation in the promoter CpG island. One exception to this rule is observed for MCF7, where there is no clear correlation between the expression of CLCA2 and the methylation status of the promoter CpG island in this cell line. One explanation for this lack of correlation in MCF7 could come from the fact that the alteration of the function of a single gene, such as CLCA2, cannot account for all the breast cancer cases, including MCF7. On the other hand, all the breast tumours and cell lines, which express CLCA2, had low or no methylation of the promoter CpG island.
In conclusion, aberrant promoter methylation and associated transcriptional silencing are now recognized as a major mechanism of tumour suppressor gene inactivation. CLCA2 resembles other tumour suppressor genes, such as SLIT2 (Dallol et al., 2002) , LOT1 (Abdollahi et al., 2003) and RASSF1A (Dammann et al., 2003) , in that epigenetic inactivation appears to be much more frequent than mutational mechanisms. CLCA2 is a calcium-activated chloride channel, the exact function of which is still unclear. It has been demonstrated that the activity of chloride channels, like CLCA2 varies during the cell cycle. Chloride current peaks in G1 and is lowest in S phase (Bubien et al., 1990; Ullrich and Sontheimer, 1997) . Moreover, the blockade of chloride channels was found to enhance cell proliferation (Deane and Mannie, 1992) . Suppression of the chloride channel activity of CLCA2 in the breast epithelium could, therefore, be responsible for the enhancement of abnormal cell proliferation, which ultimately leads to the development of a malignant phenotype. A more detailed biochemical, molecular and cellular analysis of the expression of CLCA2 and its impact on the cell cycle progression will be needed to provide a clearer understanding to its role in breast cancer.
Materials and methods
Tissue samples
We analysed a total of 12 invasive breast carcinomas and corresponding normal tissue that were obtained at the time of surgical resection. These tumours were detected either by mammographic screening or had presented symptomatically. None of the tumours occurred in women with a known family history of breast cancer or other cancers. All tissues were microdissected free of normal surrounding tissue, although a contamination with surrounding normal breast tissue could not be ruled out. In addition, DNA obtained from an additional 46 breast tumours (frozen tissue) and nine breast cancer cell lines was analysed for CLCA2 mutations and promoter CpG island methylation. We also used as controls, DNA extracted from lymphocytes of normal individuals.
Cell lines and 5-aza-2
0 -dC treatment Breast cancer cell lines were routinely maintained in DMEM supplemented with 10% FBS at 371C, 10% CO 2 . The demethylating agent 5-aza-2 0 -dC (Sigma, MO, USA) was freshly prepared in double-distilled H 2 O and filter sterilized. Cells (5-10 Â 10 5 ) were plated in a 100-cm 2 tissue culture dish in DMEM supplemented with 10% FBS at 371C, 10% CO 2 . The next day, cells were treated with 10 mM of 5-aza-2 0 -dC. The medium containing the demethylating agent was replaced every day for 10 days. After 10 days of treatment, total RNA was prepared using TRIzol (Invitrogen, CA, USA), according to the manufacturer's instructions. The total genomic DNA was prepared using proteinase K digestion as previously described (Sossey-Alaoui et al., 2002a) . with an expected PCR product size of 629 bp. We used total RNA extracted from primary breast tumours as well as from untreated and 5-aza-2 0 -dC treated breast cancer cell lines to monitor the expression of CLCA2. Panels of normalized, firststrand cDNA preparations from RNA from various human and mouse tissues were purchased from BD Biosciences (CA) and used for RT-PCR to determine the tissue distribution of CLCA2 expression. PCR was carried out in an MJ Research Inc., Thermocycler (Walthan, MA, USA) using the following conditions: 951C for 3 min followed by 30 cycles of 951C for 30 s, 601C for 30 s and 721C for 30 s. A final cycle of 721C for 5 min was applied to ensure complete elongation of the PCR products. The PCR samples were then cooled to 41C before being resolved by agarose gel electrophoresis.
Expression analysis of CLCA2
Mutation analysis of primary tumours and cell lines
Intron-exon boundaries were determined by aligning the cDNA sequence for CLCA2 (GenBank Accession Number NM_006536) against BAC clone RP11-444C12 (GenBank Accession Number AC119749), which contains the entire sequence of the CLCA2 gene. The WAVE instrument (Transgenomic, NE, USA) was utilized to perform denaturing high-performance liquid chromatography (DHPLC) and search for mutations in CLCA2 as described elsewhere (Sossey-Alaoui et al., 2002b) . Oligonucleotide primers specific to each exon of CLCA2 (Table 2) were used for the mutational screening of primary breast tumours and cell lines. Owing to the large size of exons 6 and 14, we used two overlapping amplicons to analyse each one of these two exons (Table 2) . Mutations were verified by restriction analysis in the tumour and normal DNAs, when the nucleotide substitution results in the creation or abolition of an endonuclease restriction site. In cases where the mutation does not alter the restriction profile of the tumour, an oligonucleotide primer was designed where the nucleotide adjacent to the mutation is modified in a way that, together with the mutation, will create or abolish a restriction site in the tumour but not in the normal control.
Bisulphite modification and methylation analysis
Bisulphite DNA sequencing was performed as described in Frommer et al. (1992) , with minor adjustments to optimize the conditions to our material. Briefly, 1-2 mg of genomic DNA was denatured in 0.3 M NaOH for 30 min at 421C, and then the unmethylated cytosine residues were sulphonated by incubation in 3.12 M sodium bisulphite (pH 5.0; Sigma)/5 mM hydroquinone (Sigma, MO, USA) at 551C for 16 h. The sulphonated DNA was recovered using the QIAquick Gel Extraction system (Qiagen, MA, USA), according to the manufacturer's recommendations. The conversion reaction was completed by desulphonating in 0.3 M NaOH for 5 min at room temperature. The DNA was ethanol precipitated and resuspended in double-distilled water.
The CLCA2 putative promoter region was predicted from the genomic sequence of BAC clone RP11-444C12 upstream of the first exon of CLCA2 gene, using the PromoterInspector prediction software (http://www.genomatix.ed). The region (279 bp) that covers the CpG island was amplified from breast tumours and cell lines not expressing or expressing CLCA2 using primers 5 0 -GGGATTTATTATTGTTTTTATTTTTA GAT-3 0 and 5 0 -ATCTACCCACTATAATACCCCCTAC-3 0 , which were designed with the assistance of the MethPrimer software (http://itsa.ucsf.edu/Burolab/methprimer/index1.html). In total, 20-50 ng of bisulphite-treated DNA was used as template in each PCR reaction using the following conditions: 951C for 5 min, followed by 40 cycles of 15 s of denaturation at 951C, 20 s at 551C and 25 s of extension at Epigenetic silencing of CLCA2 in breast cancer X Li et al 721C. The PCR reaction was terminated with an additional 7 min of extension and cooled to 41C. The PCR products were resolved on a 2% agarose gel, stained with ethidium bromide, and the 279-bp bands were excised and gel was purified using the QIAquick Gel Extraction system (Qiagen, MA, USA). The purified PCR products were cloned into the pCR2 Á 1 vector (Invitrogen, CA, USA), and at least 10 clones were sequenced in each experiment. The methylation status at each CpG site of the CLCA2 gene promoter was analysed using the MethTools software (http://genome.imb-jena.de/methtools/).
